Nearly six months after first expressing concern about the validity of a 2010 paper on multiple sclerosis, Nature Medicine has retracted the article for containing “erroneous” data — which in this case don’t seem to have existed, making them more fabricated than wrong.
The paper, “Crucial role of interleukin-7 in T helper type 17 survival and expansion in autoimmune disease,” came from a group led by Jingwu Zhang, who at the time ran GlaxoSmithKline’s Research and Development Center in Shanghai.
In what could be a significant blow to a major pharmaceutical company, Nature Medicine is reportedly set to retract a 2010 article by a group of researchers affiliated with a Chinese arm of the drug giant GlaxoSmithKline.
We’re not the first to report the news — you can read coverage of it on In the Pipeline and Pharmalot, for starters — which includes the revelation that Glaxo has fired Jingwu Zang, a co-author of the suspect paper and former senior vice president and head of research and development at the Shanghai facility: in other words, a big fish. (Big enough to have a profile in, well, Nature Reviews Drug Discovery.)
PLoS One and Nature Medicine have issued corrections for papers by Zhiguo Wang, the former Montreal Heart Institute researcher who resigned in September following an investigation into image manipulation in his lab.
We’ve been reporting on the case of Zhiguo Wang, the Montreal Heart Institute researcher who was dismissed earlier this month for scientific misconduct. In the announcement about Wang’s dismissal, the institute said it had requested the retraction of three papers other than the two that Wang had himself retracted earlier this summer, making a total of five.
This is the second retraction of a paper by Potti, who resigned from his post at Duke in November in the midst of an investigation into scientific misconduct. The first retraction was in the Journal of Clinical Oncology.